Ignite Creation Date:
2024-07-17 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06471946
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-17
Brief Title:
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS
Sponsor:
Navy General Hospital Beijing
Organization:
Navy General Hospital Beijing
Study Overview
Official Title:
Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this phase 12 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS
Detailed Description:
The investigators will evaluate 2 year overall survivalOS after transplantation in patients with higher-risk MDS Progression free survival PFS incidence of acute GVHD non-relapse mortality NRM graft-versus-host disease GVHD-free relapse-free survivalGRFS and incidence of chronic GVHD at 1 and 2 years after transplantation will be counted
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None